Current and historical daily PE Ratio for Parnell Pharmaceuticals Holdings Ltd (
) from 2014 to Apr 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Parnell Pharmaceuticals stock (PARNF) PE ratio as of Apr 26 2024 is 0.
More Details
Parnell Pharmaceuticals Holdings Ltd (PARNF) PE Ratio (TTM) Chart
Parnell Pharmaceuticals Holdings Ltd (PARNF) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 0
- 1
| Parnell Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
Parnell Pharmaceuticals Holdings Ltd (PARNF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Parnell Pharmaceuticals Holdings Ltd
NAICS : 325412
SIC : 2834
ISIN : AU0000XINEU9
Compare
Compare
Traded in other countries / regions
PARNF.USA IPO Date
2014-06-18Description
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers